natgillin/translations-raw huggingface dataset:
A part of the pre-filled pen, the needle cover, contains latex.
Jedan dio napunjene brizgalice, zaštitni poklopac za iglu, sadrži lateks.
A part of the pre-filled syringe, the needle cover, contains latex.
Jedan dio napunjene štrcaljke, zaštitni poklopac za iglu, sadrži lateks.
A Patient Alert Card
Karticu s upozorenjima za bolesnika
A patient alert card including a core text agreed by the CHMP
Karticu s upozorenjima za bolesnika koja uključuje dogovoreni tekst od strane CHMP-a
A patient booklet will also be distributed to all patients who are prescribed Thymanax so that they are aware of the risk to the liver, the importance of monitoring liver function and the signs of liver problems to look out for.
Svim bolesnicima kojima je propisan lijek Thymanax bit će dostavljena i brošura za bolesnike kako bi bili upoznati s rizicima za jetru, važnosti praćenja funkcije jetre i znakovima problema u funkciji jetre na koje trebaju obratiti pozornost.
A patient booklet will also be distributed to all patients who are prescribed Valdoxan so that they are aware of the risk to the liver, the importance of monitoring liver function and the signs of liver problems to look out for.
Svim bolesnicima kojima je propisan lijek Valdoxan bit će dostavljena i brošura za bolesnike kako bi bili upoznati s rizicima za jetru, važnosti praćenja funkcije jetre i znakovima problema u funkciji jetre na koje trebaju obratiti pozornost.
A patient is defined as hyperresponsive to inhaled mannitol and must not be prescribed the therapeutic dose regimen if they experience any of the following during the initiation dose assessment:
Smatra se da u pacijenta postoji hiperreaktivnost na inhalirani manitol te mu se ne smije propisati terapijska doza ako tijekom uzimanja početne doze u bilo kojem od sljedećih slučajeva:
A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.
Bolesnik koji primjenjuje oralni rivastigmin u dozi od 12 mg/dan može prijeći na transdermalni flaster u dozi od 9,5 mg/24 h.
A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Bolesnik koji primjenjuje oralni rivastigmin u dozi od 3 mg/dan može prijeći na transdermalni flaster u dozi od 4,6 mg/24 h.
A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Bolesnik koji primjenjuje oralni rivastigmin u dozi od 6 mg/dan može prijeći na transdermalni flaster u dozi od 4,6 mg/24 h.
A patient on a stable and well tolerated dose of 9 mg/day oral rivastigmine can be switched to
Bolesnik na stabilnoj dozi od 9 mg/dan oralnog rivastigmina koju dobro podnosi može prijeći na transdermalni flaster u dozi od 9,5 mg/24 h.
A patient was classified as a ‘responder’ if the number of seizures in the second month of treatment was at least 50% lower than the number in the month before treatment was started.
Bolesnici su klasificirani kao „odgovaratelji” ako se broj napadaja u drugom mjesecu smanjio za najmanje 50% i odnosu na broj napadaja u mjesecu kada je započeto liječenje.
A patient was considered RBC or platelet transfusion independent during the treatment period if the subject had no RBC or platelet transfusions during any consecutive 56 days during the reporting period, respectively.
Smatralo se da bolesnik nije ovisan o transfuziji eritrocita ili trombocita tijekom razdoblja liječenja ako taj ispitanik nije primio transfuziju eritrocita odnosno trombocita tijekom bilo kojih uzastopnih 56 dana tijekom razdoblja izvjšćivanja.
A patient who experiences dose limiting adverse reactions on either component alone may be switched to Rasilamlo containing a lower dose of that component to achieve similar blood pressure reductions.
Bolesnik koji tijekom terapije jednom od komponenti osjeti nuspojave zbog kojih je potrebno ograničiti dozu te komponente, može se prebaciti na Rasilamlo, koji sadrži nižu dozu te komponente, i postići sličan učinak na sniženja krvnog tlaka.
A patient who requires surgery while on Inflectra should be closely monitored for infections, and appropriate actions should be taken.
Bolesnika kojemu je za vrijeme liječenja lijekom Inflectra potrebna operacija nužno je pomno nadzirati kako bi se utvrdile eventualne infekcije i poduzele odgovarajuće mjere.
A patient who requires surgery while on Remsima should be closely monitored for infections, and appropriate actions should be taken.
Bolesnika kojemu je za vrijeme liječenja lijekom Remsima potrebna operacija nužno je pomno nadzirati kako bi se utvrdile eventualne infekcije i poduzele odgovarajuće mjere.
A patient who requires surgery while on Simponi should be closely monitored for infections, and appropriate actions should be taken.
Bolesnika kojemu je za vrijeme liječenja lijekom Simponi potrebna operacija nužno je pomno pratiti zbog infekcija, te poduzeti odgovarajuće mjere.
A patient with poor metaboliser status will possess two loss-of- function alleles as defined above.
Bolesnici sa statusom sporih metabolizatora imaju 2 nefunkcionalna alela kako je definirano gore.
A patient with such elevations of transaminases or bilirubin should stop taking naltrexone/bupropion and notify their prescribing physician.
Bolesnik s takvim povišenjem transaminaza ili bilirubina mora prekinuti uzimati naltrekson / bupropion i obavijestiti svog nadležnog liječnika.
A patient with type 2 diabetes previously well controlled on Efficib who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Ako se razviju laboratorijski nalazi koji odstupaju od normalnih vrijednosti ili klinička bolest (posebno nejasna i loše definirana bolest) u bolesnika s prethodno dobro reguliranim dijabetesom tipa 2 lijekom Efficib, treba odmah potražiti znakove ketoacidoze ili laktacidoze.
A patient with type 2 diabetes previously well controlled on Janumet who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Ako se razviju laboratorijski nalazi koji odstupaju od normalnih vrijednosti ili klinička bolest (posebno nejasna i loše definirana bolest) u bolesnika s prethodno dobro reguliranim dijabetesom tipa 2 lijekom Janumet, treba odmah potražiti znakove ketoacidoze ili laktacidoze.
A patient with type 2 diabetes previously well controlled on Ristfor who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Ako se razviju laboratorijski nalazi koji odstupaju od normalnih vrijednosti ili klinička bolest (posebno nejasna i loše definirana bolest) u bolesnika s prethodno dobro reguliranim dijabetesom tipa 2 lijekom Ristfor, treba odmah potražiti znakove ketoacidoze ili laktacidoze.
A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Ako se razviju laboratorijski nalazi koji odstupaju od normalnih vrijednosti ili klinička bolest (posebno nejasna i loše definirana bolest) u bolesnika s prethodno dobro reguliranim dijabetesom tipa 2 lijekom Velmetia, treba odmah potražiti znakove ketoacidoze ili laktacidoze.
A patient-level data analysis has also been performed on more than 13 900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Analiza podataka na nivou bolesnika provedena je na više od 13 900 bolesnika s malignim bolestima (kemo-, radio-, kemoradio-, ili bez terapije) koji su sudjelovali u 53 kontrolirana klinička ispitivanja koja su uključivala nekoliko epoetina.
A patient-level data analysis has also been performed on more than 13 900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Analiza podataka na nivou bolesnika provedena je na više od 13 900 bolesnika s malignim bolestima (kemo-, radio-, kemoradioterapije, ili bez terapije) koji su sudjelovali u 53 kontrolirana klinička ispitivanja koja su uključivala nekoliko epoetina.
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio- or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Analizirani su i podaci na razini bolesnika, za više od 13 900 bolesnika s karcinomom (kemoterapija, radioterapija, kemoradioterapija ili bez terapije) koji su sudjelovali u 53 kontrolirana klinička ispitivanja nekoliko epoetina.
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
U analizama podataka na razini bolesnika koji su provedeni na više od 13900 bolesnika s rakom (kemo-, radio-, kemoradio- ili bez terapije) u 53 kontrolirana klinička ispitivanja primijenjeno je nekoliko epoetina.
A patient/carer and close contacts guide
Vodič za bolesnika/njegovatelja i osobe u neposrednoj blizini
a Patients were stratified by baseline HIV-1 RNA in both studies.
a Pacijenti su bili stratificirani prema početnim vrijednostima HIV-1 RNK u oba ispitivanja.
a Patients with at least a partial response to Humira 40 mg weekly after 12 weeks of treatment. b Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders.
a Bolesnici koji su ostvarili barem djelomičan odgovor na liječenje lijekom Humira u dozi od 40 mg svaki tjedan nakon 12 tjedana liječenja. b Bolesnici koji su ispunjavali protokolom utvrđene kriterije za gubitak odgovora ili izostanak poboljšanja morali su prekinuti ispitivanja i vodili su se kao bolesnici bez odgovora
a patients with measurable disease at baseline
a bolesnici s mjerljivom bolešću na početku ispitivanja
A patient’s breakthrough pain was considered to have responded to treatment if there was a reduction of at least two points.
Smatrano je da je probojna bol bolesnika odgovorila na liječenje ako je nastupilo smanjenje od najmanje dva boda.
A patient’s guide informing about the possibility of two co-existing formulations in the EU market, and the differences concerning their administration, in order to address the important potential risk of medication error for deferasirox
Vodič za bolesnike u kojem ih se obavještava o mogućnosti istodobnog postojanja dvije formulacije na tržištu EU i o razlikama vezanim uz njihovu primjenu, radi ukazivanja na važne potencijalne rizike od medikacijskih pogrešaka za deferasiroks
A peak Factor X level of 90% of normal is required in a 40 kg child.
Vršna razina faktora X od 90 % normalne vrijednosti potrebna je u djeteta od 40 kg.
a Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients
a Pedijatrijski odgovori ACR 30/50/70 nakon 48 tjedana terapije bili su značajno veći nego u skupini koja je uzimala placebo bp=0,015 cp=0,031
a Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients
aPedijatrijski odgovori ACR 30/50/70 nakon 48 tjedana terapije bili su značajno veći nego u skupini koja je uzimala placebo bp=0,015 cp=0,031
A penile modeling procedure is performed 1 to 3 days after the second injection of each treatment cycle.
Postupak modeliranja penisa provodi se 1-3 dana nakon druge injekcije svakog ciklusa liječenja.
A penile modeling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle.
Postupak modeliranja penisa proveden je bolesnicima u ispitivačkom centru 1 do 3 dana nakon druge injekcije u ciklusu.
a Percent of patients achieving PASI75 response was calculated as center-
a Postotak bolesnika s rezultatom PASI 75 izražen kao stopa prilagođena
a Percent of patients achieving PASI75 response was calculated as center-
a Postotak bolesnika s rezultatom PASI 75, izražen kao stopa prilagođena
A percentage of 71% of all sexual attempts reported in the clinical trials had successful penetration compared to 44% of all attempts in the placebo group.
Klinička ispitvanja su pokazala da je uspješna penetracija postignuta u 71% svih pokušaja spolnog odnosa u usporedbi s 44% svih pokušaja u skupini koja je primala placebo.
A peri and postnatal toxicity study performed in rabbits with thalidomide administered at doses up to 500 mg/kg/day resulted in abortions, increased stillbirths and decreased pup viability during lactation.
Ispitivanja perinatalne i postnatalne toksičnosti provedena na kunićima uz primjenu talidomida u dozama do 500 mg/kg/dan rezultirala su pobačajima, povećanim brojem mrtvorođene mladunčadi i smanjenom sposobnošću preživljenja mladunčadi u razdoblju sisanja.
A peri-postnatal study has not been conducted with buprenorphine/naloxone; however, maternal oral administration of buprenorphine at high doses during gestation and lactation resulted in difficult parturition (possible as a result of the sedative effect of buprenorphine), high neonatal mortality and a slight delay in the development of some neurological functions (surface righting reflex and startle response) in neonatal rats.
Nije provedeno peri- postnatalno ispitivanje buprenorfina/naloksona; međutim, peroralna primjena visokih doza buprenorfina u ženki tijekom gestacije i laktacije rezultirala je otežanim okotom (vjerojatno posljedica sedativnog učinka buprenorfina), visokim neonatalnim mortalitetom i blago odgođenim razvojem nekih neuroloških funkcija (refleks uspravljanja i reakcija trzanja) u novorođenih štakora.
a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e. a thiazolidinedione) when use of a PPAR agonist is appropriate and when diet and exercise plus the PPAR agonist alone do not provide adequate glycaemic control.
s agonistom receptora za aktivator proliferacije peroksisoma-gama (engl. peroxisome proliferator-activated receptor gamma, PPAR) (tj. tiazolidindionom), kada je primjena agonista PPAR primjerena te kada dijeta i tjelovježba uz samo agonist PPAR ne omogućavaju odgovarajuću regulaciju glikemije.
A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Osoba čija tjelesna težina iznosi 80 kg, a visina 1,80 m ima tjelesnu površinu od 2,00 m2 te mora uzimati 5 tableta od 500 mg dvaput dnevno.
A PET scan with flutemetamol (18F) should be requested by clinicians experienced in the clinical management of neurodegenerative disorders.
PET snimanje s flutemetamolom (18F) trebali bi indicirati zdravstveni djelatnici s iskustvom u kliničkom liječenju neurodegenerativnih poremećaja.
A pharmacodynamic interaction
Mehanizam nepoznat
A pharmacodynamic interaction study in healthy volunteers demonstrated that administration of loperamide and Aptivus, co- administered with low dose ritonavir, does not cause any clinically relevant change in the respiratory response to carbon dioxide.
Ispitivanje farmakodinamičkih interakcija na zdravim dobrovoljcima pokazalo je da primjena loperamida i Aptivusa s niskom dozom ritonavira ne izaziva klinički značajne promjene u respiratornoj reakciji na CO2.
A pharmacodynamic model based on the Phase III trial data predicts that around 15% of the patients develop antibodies in 6 months at the recommended dose regimen (200 mg every 2 weeks following a loading dose) without MTX co-treatment.
Farmakodinamički model koji se temeljio na podacima iz III. faze istraživanja predviđao je da bi oko 15% bolesnika moglo stvoriti protutijela unutar prvih 6 mjeseci liječenja koje se provodi u skladu s preporučenim doziranjem (200 mg svaka 2 tjedna, nakon početne doze) i bez prateće primjene MTX
A pharmacodynamic study with exenatide demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose.
Farmakodinamičko ispitivanje s eksenatidom pokazalo je da se u bolesnika sa šećernom bolešću tipa 2 (n=13), kao odgovor na intravenski bolus glukoze, ponovno uspostavlja prva faza lučenja inzulina i poboljšava druga faza lučenja inzulina.
A pharmacokinetic analysis predicted a drug-related QTc interval prolongation at 80 mg of 14 msec with an upper bound of 16 msec (90% CI).
Farmakokinetička analiza predvidjela je produljenje QTc intervala povezano s lijekom od 14 msek za dozu od 80 mg, uz gornju granicu od 16 msek (CI 90%)
A pharmacokinetic analysis with TAGRISSO predicted a concentration-dependent increase in QTc interval prolongation.
Farmakokinetička analiza s lijekom TAGRISSO predvidjela je povećanje produljenja QTc intervala ovisno o koncentraciji.
A pharmacokinetic interaction between vinflunine and pegylated/liposomal doxorubicin was observed, resulting in a 15% to 30% apparent increase in vinflunine exposure and a 2 to 3-fold apparent decrease of doxorubicin AUC, whereas for doxorubicinol, the concentrations of the metabolite were not affected.
Primijećena je farmakokinetička interakcija izmeñu vinflunina i pegiliranog/liposomalnog doksorubicina koja je za posljedicu imala 15%-tno do 30%-tno prividno povećanje izloženosti vinfluninu i dvostruko do trostruko prividno smanjenje AUC-a doksorubicina, dok za doksorubicinol koncentracije metabolita nisu bile promijenjene.
A pharmacokinetic phase I study was performed in 2 groups of patients with renal impairment classified according to the calculated creatinine clearance (CrCl) values: group 1 (n=13 patients) with moderate impairment (40 mL/min  CrCl  60 mL/min) and group 2 (n=20 patients) with severe impairment (20 mL/min  CrCl  40 mL/min).
Provedeno je farmakokinetičko ispitivanje faze I na 2 skupine bolesnika s oštećenjem bubrega razvrstanih prema izračunatim vrijednostima klirensa kreatinina (CrCl): skupina 1 (n=13 bolesnika) s umjerenim oštećenjem ((40 mL/min  CrCl  60 mL/min) i skupina 2 (n=20 bolesnika) s teškim oštećenjem (20 mL/min  CrCl  40 mL/min).
A pharmacokinetic study has been performed in non-HIV infected adult patients with various degrees of hepatic impairment.
Provedeno je farmakokinetičko ispitivanje u odraslih pacijenata bez infekcije HIV-om koji su imali različiti stupanj oštećenja funkcije jetre.
A pharmacokinetic study in older healthy volunteers did not show a significant difference in pharmacokinetic parameters compared with younger adults.
Farmakokinetičko ispitivanje u starijih zdravih dobrovoljaca nije pokazalo značajnu razliku u farmakokinetičkim parametrima, u usporedbi s mlađim odraslim osobama.
A pharmacokinetic study in paediatric patients aged 2 months to <18 years demonstrated very low plasma exposure to travoprost free acid, with concentrations ranging from below the 10 pg/mL assay limt of quantitation (BLQ) to 54.5 pg/mL.
Ispitivanje farmakokinetike u pedijatrijskih bolesnika u dobi od 2 mjeseca do < 18 godina pokazalo je vrlo nisku izloženost travoprost slobodnoj kiselini u plazmi, s koncentracijama u rasponu od ispod 10 pg/ml granice kvantifikacije testa (BLQ) do 54,5 pg/ml.
A pharmacokinetic study in patients with chemotherapy-induced anaemia treated with 6.75 µg/kg darbepoetin alfa administered SC every 3 weeks in combination with chemotherapy was conducted which allowed for full characterisation of the terminal half-life.
Farmakokinetičko ispitivanje kod bolesnika s anemijom induciranom kemoterapijom liječenih sa 6,75 µg/kg darbepoetina alfa primijenjenog supkutano svaka 3 tjedna u kombinaciji s kemoterapijom, omogućilo je potpuno određivanje terminalnog poluvijeka života.
A pharmacokinetic study in patients with ESRD undergoing hemodialysis demonstrated a 36% increase in mean lomitapide plasma concentration compared to matched healthy controls.
Farmakokinetičko ispitivanje u bolesnika s ESRD koji su bili na hemodijalizi pokazalo je povećanje srednje vrijednosti koncentracije lomitapida u plazmi od 35% u usporedbi sa zdravim kontrolnim ispitanicima.
A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. (see section 4.2)
Farmakokinetičko ispitivanje u ispitanika s cirozom jetre (Child-Pugh stadij A, B i C) pokazalo je slična povećanja izloženosti brivaracetamu neovisno o težini bolesti (50%, 57% odnosno 59%) u odnosu na uparene zdrave kontrolne ispitanike (vidjeti dio 4.2).
A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥ 60 ml/min/1.73 m2, n=12), Mild (CrCL = 40-59 ml/min/1.73 m2, n=10), Moderate (CrCL = 20-
Provedeno je farmakokinetičko ispitivanje u bolesnika s različitim stupnjevima oštećenja bubrega koji su bili podijeljeni prema vrijednostima klirensa kreatinina (CrCL) u sljedeće skupine: normalno (CrCL ≥ 60 ml/min/1,73 m2, n=12), blago (CrCL=40-59 ml/min/1,73 m2, n=10), umjereno (CrCL=20-39 ml/min/1,73 m2, n=9) i teško (CrCL
A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥ 60 ml/min/1.73 m2, n=12), Mild (CrCL=40-59 ml/min/1.73 m2, n=10), Moderate (CrCL=20-39 ml/min/1.73 m2, n=9), and Severe (CrCL < 20 ml/min/1.73 m2, n=3).
Provedeno je farmakokinetičko ispitivanje u bolesnika s različitim stupnjevima oštećenja bubrega koji su bili podijeljeni prema vrijednostima klirensa kreatinina (CrCL) u sljedeće skupine: normalno (CrCL ≥ 60 ml/min/1,73 m2, n = 12), blago (CrCL = 40-59 ml/min/1,73 m2, n = 10), umjereno (CrCL = 20-39 ml/min/1,73 m2, n = 9) i teško (CrCL < 20 ml/min/1,73 m2, n = 3).
A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥ 60 ml/min/1.73 m2, n=12), Mild (CrCL=40-59 ml/min/1.73 m2, n=10), Moderate (CrCL=20-39 ml/min/1.73 m2, n=9), and Severe (CrCL < 20 ml/min/1.73 m2, n=3).
Provedeno je farmakokinetičko ispitivanje u bolesnika s različitim stupnjevima oštećenja bubrega koji su bili podijeljeni prema vrijednostima klirensa kreatinina (CrCL) u sljedeće skupine: normalno (CrCL ≥ 60 ml/min/1,73 m2, n=12), blago (CrCL=40-59 ml/min/1,73 m2, n=10), umjereno (CrCL=20-39 ml/min/1,73 m2, n=9) i teško (CrCL < 20 ml/min/1,73 m2, n=3).
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat HCl revealed that 99% of the radiolabeled dose recovered in plasma was comprised of unchanged migalastat (77%) and 3 dehydrogenated O- glucuronide conjugated metabolites, M1to M3 (13%).
Farmakokinetičko ispitivanje u zdravih muških dobrovoljaca s dozom od 150 mg [14C]-migalastata HCl pokazalo je da se 99 % radioaktivno označene doze nađene u plazmi sastojalo od neizmijenjenog migalastata (77 %) te od tri dehidrogenirana konjugirana metabolita O-glukuronida M1 do M3 (13 %).
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat hydrochloride revealed that approximately 77% of the radiolabeled dose was recovered in urine.
Farmakokinetičko ispitivanje u zdravih muških dobrovoljaca s dozom od 150 mg [14C]- migalastatklorida pokazalo je da je otprilike 77 % radioaktivno označene doze pronađeno u urinu.
A pharmacokinetic trial in subjects with hepatic impairment has not been conducted.
Nije provedeno farmakokinetičko ispitivanje u bolesnika s oštećenjem funkcije jetre.
A pharmacokinetic/pharmacodynamic analysis suggested a relationship between crizotinib plasma concentration and QTc.
Farmakokinetička/farmakodinamička analiza ukazala je na to da postoji povezanost između koncentracije krizotiniba u plazmi i QTc-intervala.